Categories: Corporate and commercial, Health Care, Information and Communication Technology, Life Sciences, Pharma, Biotech, Startup Desk, Deals & Cases
Ikerian, a healthcare software platform company that organizes multimodal data at-scale, closes the first tranche of USD 8m Series B Financing to advance its AI platform alongside. The Series B Financing Round is led by strategic investor Sanoptis with participation of the existing investors Topcon Healthcare, Zürcher Kantonalbank and Verve Ventures. Alongside the equity investment, Ikerian and Sanoptis have entered into a commercial agreement to support the distribution of the RetinAI Discovery® platform and its AI models at-scale within the European Sanoptis network. The AI and imaging platform is aimed at improving diagnostic and treatment pathways towards personalized patient care.
VISCHER advises Ikerian with Matthias Staehelin (Partner) and Timothy Woodtli (Associate), both Corporate/M&A.
Author: Matthias Staehelin
Matthias Staehelin
Attorney at Law and Civil Law Notary (BS/BL)
- Partner
- +41 58 211 33 53
- [email protected]
